Efficacy News and Research

RSS

IRIDEX’ Micropulse technology safe, durable for treating glaucoma

IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma.

22 May 2014

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of the European Medicines Agency.

22 May 2014

Eisai launches new class of epilepsy treatment Fycompa in France

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.

22 May 2014

SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

SinoVeda Canada Inc. today announces positive clinical results for EffectiCal® from its 24-week double-blind, randomized comparative clinical trial in post-menopausal women.

22 May 2014

Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

According to a new systematic review article, radiofrequency ablation and complete endoscopic resection are equally effective in the short-term treatment of dysplastic Barrett's esophagus, but adverse event rates are higher with complete endoscopic resection.

22 May 2014

VTT scientists discover unknown Cent-1 molecule that kills cancer cells

A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells.

22 May 2014

Little efficacy difference between old and new antipsychotics

Older and second-generation long-acting antipsychotics have broadly similar clinical efficacy, shows a randomised trial in JAMA.

21 May 2014

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Disease progression-free survival is similar for patients with non-small-cell lung cancer and epidermal growth factor receptor mutations whether they receive erlotinib or gefitinib, show the results of a South Korean study.

21 May 2014

Bendamustine modestly efficacious but well tolerated in SCLC

Patients with relapsed or treatment-resistant small-cell lung cancer can achieve modest survival benefits with few side effects when treated with bendamustine, report US researchers.

21 May 2014

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

Southern Research Institute today announced a new service offering - a novel in vitro 12-cell line panel assay designed to predict drug activity and improve the success rate of drugs tested in xenograft models.

21 May 2014

New cancer drug candidates can be identified faster by using computer-assisted screening

21 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients.

21 May 2014

New antibody can improve quality of life for individuals with asthma

Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced the presentation by Juventas Therapeutics of their positive four-month results for their STOP-HF Trial.

20 May 2014

Efficacy News and Research

IRIDEX’ Micropulse technology safe, durable for treating glaucoma

EMA grants Advanced Therapy Medicinal Product classification for TxCell's Col-Treg

Eisai launches new class of epilepsy treatment Fycompa in France

SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

Effects of radiofrequency ablation and complete endoscopic resection are equal in dysplastic Barrett's esophagus

VTT scientists discover unknown Cent-1 molecule that kills cancer cells

Little efficacy difference between old and new antipsychotics

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Bendamustine modestly efficacious but well tolerated in SCLC

New in vitro 12-cell line panel assay predicts anti-cancer drug activity

New cancer drug candidates can be identified faster by using computer-assisted screening

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

New antibody can improve quality of life for individuals with asthma

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Pemetrexed plus erlotinib shows benefits in NSCLC

BioLineRx announces financial results for Q1 2014, provides operational update

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News